|
PT2029602E
(pt)
|
2006-05-31 |
2010-07-08 |
Galapagos Nv |
Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
|
|
AR063706A1
(es)
*
|
2006-09-11 |
2009-02-11 |
Cgi Pharmaceuticals Inc |
Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
|
|
CL2008002793A1
(es)
*
|
2007-09-20 |
2009-09-04 |
Cgi Pharmaceuticals Inc |
Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
|
|
WO2009053269A1
(en)
*
|
2007-10-23 |
2009-04-30 |
F. Hoffmann-La Roche Ag |
Novel kinase inhibitors
|
|
US7683064B2
(en)
|
2008-02-05 |
2010-03-23 |
Roche Palo Alto Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
US8426424B2
(en)
|
2008-05-06 |
2013-04-23 |
Cgi Pharmaceuticals, Inc. |
Certain substituted amides, method of making, and method of use thereof
|
|
ES2552320T3
(es)
|
2008-06-24 |
2015-11-27 |
F. Hoffmann-La Roche Ag |
Nuevas piridín-2-onas y piridazín-3-onas sustituidas
|
|
BRPI0913879A2
(pt)
*
|
2008-07-02 |
2019-09-24 |
Hoffmann La Roche |
fenilpirazinonas como inibidores de quinase
|
|
CA2726460C
(en)
*
|
2008-07-15 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Novel phenyl-imidazopyridines and pyridazines
|
|
WO2010006970A1
(en)
|
2008-07-18 |
2010-01-21 |
F. Hoffmann-La Roche Ag |
Novel phenylimidazopyrazines
|
|
US8476430B2
(en)
|
2008-07-24 |
2013-07-02 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
|
WO2010068806A1
(en)
*
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
|
JP5487214B2
(ja)
|
2008-12-19 |
2014-05-07 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
|
|
EP2440204B1
(en)
|
2009-06-12 |
2013-12-18 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
|
EP2464647B1
(en)
|
2009-08-11 |
2016-09-21 |
Bristol-Myers Squibb Company |
Azaindazoles as btk kinase modulators and use thereof
|
|
PT2473049T
(pt)
|
2009-09-04 |
2019-03-04 |
Sunesis Pharmaceuticals Inc |
Inibidores de tirosina quinase de bruton
|
|
US8685969B2
(en)
|
2010-06-16 |
2014-04-01 |
Bristol-Myers Squibb Company |
Carboline carboxamide compounds useful as kinase inhibitors
|
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
WO2012135631A1
(en)
|
2011-03-30 |
2012-10-04 |
Arrien Pharmaeuticals Llc |
Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
|
|
KR20140058543A
(ko)
|
2011-07-08 |
2014-05-14 |
노파르티스 아게 |
신규 피롤로 피리미딘 유도체
|
|
WO2013161848A1
(ja)
*
|
2012-04-27 |
2013-10-31 |
カルナバイオサイエンス株式会社 |
新規１，２，４－トリアジン誘導体
|
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
|
AR091273A1
(es)
*
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
|
JP6215315B2
(ja)
|
2012-06-12 |
2017-10-18 |
アッヴィ・インコーポレイテッド |
ピリジノンおよびピリダジノン誘導体
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
WO2014108820A1
(en)
*
|
2013-01-08 |
2014-07-17 |
Aurigene Discovery Technologies Limited |
Substituted 2-pyrazinone derivatives as kinase inhibitors
|
|
WO2014125410A1
(en)
*
|
2013-02-12 |
2014-08-21 |
Aurigene Discovery Technologies Limited |
N-substituted heterocyclic derivatives as kinase inhibitors
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
HRP20170217T1
(hr)
|
2013-04-25 |
2017-04-21 |
Beigene, Ltd. |
Fuzinirani heterociklički spojevi kao inhibitori protein kinaze
|
|
WO2014210087A1
(en)
|
2013-06-25 |
2014-12-31 |
Bristol-Myers Squibb Company |
Carbazole carboxamide compounds useful as kinase inhibitors
|
|
TWI648272B
(zh)
|
2013-06-25 |
2019-01-21 |
美商必治妥美雅史谷比公司 |
經取代之四氫咔唑及咔唑甲醯胺化合物
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
WO2015050703A1
(en)
*
|
2013-10-04 |
2015-04-09 |
Yi Chen |
Inhibitors of bruton's tyrosine kinase
|
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
|
AU2014360446A1
(en)
|
2013-12-05 |
2016-06-09 |
Pharmacyclics, Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
WO2015082583A1
(en)
*
|
2013-12-05 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
SI3209651T1
(sl)
|
2014-10-24 |
2019-12-31 |
Bristol-Myers Squibb Company |
Derivati karbazola
|
|
JP6592512B2
(ja)
|
2014-10-24 |
2019-10-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
三環式アトロプ異性体の化合物
|
|
EA034931B1
(ru)
|
2014-10-24 |
2020-04-08 |
Бристол-Майерс Сквибб Компани |
Индолкарбоксамидные соединения
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
EP3365340B1
(en)
|
2015-10-19 |
2022-08-10 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US20170145025A1
(en)
|
2015-11-19 |
2017-05-25 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
ES2916874T3
(es)
|
2015-12-17 |
2022-07-06 |
Incyte Corp |
Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
|
|
AU2016379372A1
(en)
|
2015-12-22 |
2018-08-02 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
CN107033069B
(zh)
*
|
2016-02-04 |
2022-03-04 |
中国科学院合肥物质科学研究院 |
一种新型布鲁顿酪氨酸激酶不可逆抑制剂
|
|
ES2906460T3
(es)
|
2016-05-06 |
2022-04-18 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
ES2905980T3
(es)
|
2016-05-26 |
2022-04-12 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
BR112018076534A2
(pt)
|
2016-06-20 |
2019-04-02 |
Incyte Corporation |
compostos heterocíclicos como imunomoduladores
|
|
US10864203B2
(en)
|
2016-07-05 |
2020-12-15 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
|
MA45669A
(fr)
|
2016-07-14 |
2019-05-22 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
|
JP7214632B2
(ja)
|
2016-07-21 |
2023-01-30 |
バイオジェン エムエー インク． |
ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
|
|
CA3033827A1
(en)
|
2016-08-16 |
2018-02-22 |
Beigene, Ltd. |
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
|
|
PT3500299T
(pt)
|
2016-08-19 |
2024-02-21 |
Beigene Switzerland Gmbh |
Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
|
|
ES2941716T3
(es)
|
2016-08-29 |
2023-05-25 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
|
AU2017382870B2
(en)
|
2016-12-22 |
2022-03-24 |
Incyte Corporation |
Benzooxazole derivatives as immunomodulators
|
|
WO2018119286A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
|
ES2874756T3
(es)
|
2016-12-22 |
2021-11-05 |
Incyte Corp |
Derivados de triazolo[1,5-A]piridina como inmunomoduladores
|
|
ES2899402T3
(es)
|
2016-12-22 |
2022-03-11 |
Incyte Corp |
Derivados de piridina como inmunomoduladores
|
|
EP3558990B1
(en)
|
2016-12-22 |
2022-08-10 |
Incyte Corporation |
Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
|
|
EP3573989A4
(en)
|
2017-01-25 |
2020-11-18 |
Beigene, Ltd. |
CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
TW202515616A
(zh)
|
2017-06-26 |
2025-04-16 |
英屬開曼群島商百濟神州有限公司 |
抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
|
|
WO2019034009A1
(en)
|
2017-08-12 |
2019-02-21 |
Beigene, Ltd. |
BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
|
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
|
IL276398B2
(en)
|
2018-01-31 |
2026-03-01 |
Deciphera Pharmaceuticals Llc |
Combination therapy for mastocytosis
|
|
KR102708177B1
(ko)
|
2018-01-31 |
2024-09-23 |
데시페라 파마슈티칼스, 엘엘씨. |
위장관 기질 종양의 치료를 위한 병용 요법
|
|
CR20200520A
(es)
|
2018-03-30 |
2021-03-09 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
WO2019217821A1
(en)
|
2018-05-11 |
2019-11-14 |
Incyte Corporation |
Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
EP3938363A1
(en)
|
2019-03-11 |
2022-01-19 |
Teva Pharmaceuticals International GmbH |
Solid state forms of ripretinib
|
|
WO2020249001A1
(zh)
|
2019-06-10 |
2020-12-17 |
百济神州瑞士有限责任公司 |
一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP4010342A1
(en)
|
2019-08-09 |
2022-06-15 |
Incyte Corporation |
Salts of a pd-1/pd-l1 inhibitor
|
|
LT4013412T
(lt)
|
2019-08-12 |
2026-03-25 |
Deciphera Pharmaceuticals, Llc |
Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
|
|
PT4013412T
(pt)
|
2019-08-12 |
2026-03-18 |
Deciphera Pharmaceuticals Llc |
Ripretinib para o tratamento de tumores estromais gastrointestinais
|
|
WO2021067217A1
(en)
|
2019-09-30 |
2021-04-08 |
Incyte Corporation |
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
BR112022009031A2
(pt)
|
2019-11-11 |
2022-10-11 |
Incyte Corp |
Sais e formas cristalinas de um inibidor de pd-1/pd-l1
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN115243681B
(zh)
|
2019-12-30 |
2024-08-16 |
德西费拉制药有限责任公司 |
1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
|
|
HRP20231699T1
(hr)
|
2019-12-30 |
2024-05-10 |
Deciphera Pharmaceuticals, Llc |
Formulacije inhibitora amorfne kinaze i postupci njihove primjene
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
|
WO2022099075A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Crystalline form of a pd-1/pd-l1 inhibitor
|
|
US11866434B2
(en)
|
2020-11-06 |
2024-01-09 |
Incyte Corporation |
Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|